Today: 5 April 2026
Subscribe
Browse Category

Stock Market 9 October 2025

Wolfspeed WOLF Stock’s Wild Comeback: From Bankruptcy to Boom – Price, News & Expert Forecasts

Wolfspeed WOLF Stock’s Wild Comeback: From Bankruptcy to Boom – Price, News & Expert Forecasts

Wolfspeed stock surged over 1,000% intraday on September 29, 2025, after emerging from Chapter 11 bankruptcy and slashing debt by about 70%. Shares traded near $30.36 on October 9, giving a market cap of $0.7–0.8 billion. Most old equity was wiped out, with existing shareholders retaining only 3–5% of the company. Analysts rate the stock a Hold, with average 12-month price targets of $8–10.
9 October 2025
·
Ferrari Stock Skids as EV Ambitions Shift: Inside RACE’s High-Octane Gamble

Ferrari Stock Skids as EV Ambitions Shift: Inside RACE’s High-Octane Gamble

Ferrari shares plunged nearly 12% to about $430 after its Capital Markets Day, erasing year-to-date gains and leaving the stock flat versus a year ago. Market cap now stands near $75 billion, more than double Porsche’s. The company announced €3.5 billion in dividends and a €3.5 billion buyback through 2030. Insiders, led by Exor, control about 48% of voting power.
9 October 2025
··
PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

PepsiCo (PEP) Stock: Q3 Earnings Surprise, “Ozempic Effect” Fears & Activist Investor Shake-Up – What’s Next?

PepsiCo shares trade near $139, down 6% in a month and 22% below last year’s high. Q3 revenue rose 2.6% to $23.94 billion, topping estimates, but North American snack and beverage volumes fell. Elliott Management disclosed a $4 billion stake, urging changes. Steve Schmitt was named CFO on Oct. 9, replacing retiring Hugh Johnston.
9 October 2025
··
Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray’s 300% Rally and Surprise Profit: Is the Cannabis Comeback Real?

Tilray Brands posted record Q1 2026 revenue of $209.5 million and a surprise net profit of $1.5 million, sending shares up over 10% pre-market. The stock has quadrupled since July 2025, lifted by optimism over potential U.S. cannabis reform and recent political endorsements. Wall Street remains cautious, with a consensus “Hold” rating and a $1.90 price target. Volatility remains high as investors watch for policy changes and earnings updates.
9 October 2025
··
Jamie Dimon’s Dire Warning: “Serious” Stock Market Correction Could Hit Soon

Jamie Dimon’s Dire Warning: “Serious” Stock Market Correction Could Hit Soon

JPMorgan CEO Jamie Dimon warned U.S. stocks could face a “significant correction” within 6 to 24 months, citing geopolitical tensions, heavy fiscal spending, and global military buildups. He said markets are showing “unrestrained optimism” and compared current AI-driven rallies to past bubbles. Dimon remains only “mildly” concerned about inflation but said a recession is still possible by 2026.
9 October 2025
·
UiPath Stock Skyrockets on ‘Agentic AI’ Boom – AI Deals & Earnings Fuel Rally

UiPath Stock Skyrockets on ‘Agentic AI’ Boom – AI Deals & Earnings Fuel Rally

UiPath shares jumped nearly 20% in early October 2025, hitting $15.58 after new AI partnerships with OpenAI, Google, NVIDIA, and Snowflake. Quarterly revenue rose 14.6% to $362 million, with a swing to a GAAP profit. Management raised full-year guidance, but analysts remain cautious, with most ratings at Hold and a price target near $13–14. Trading volumes doubled as investors reacted to the AI announcements.
9 October 2025
··
Mystery $75 M Bet Propels Tiny POET Technologies to New Highs Amid AI Frenzy

Mystery $75 M Bet Propels Tiny POET Technologies to New Highs Amid AI Frenzy

POET Technologies announced a $75 million private placement from a single institutional investor on Oct. 7, raising its cash reserves above $150 million with no debt. Shares surged 23.5% to $7.88, trading volume hit 41 million, and call option activity spiked as retail traders piled in. The company remains pre-revenue and unprofitable, with its valuation far ahead of fundamentals.
9 October 2025
···
Stocks Soar to Record Highs, Gold Tops $4,000 – What’s Driving 2025’s Historic Rally?

Stocks Soar to Record Highs, Gold Tops $4,000 – What’s Driving 2025’s Historic Rally?

The S&P 500 and Nasdaq hit record closes on Oct. 8, with the S&P up 0.6% to 6,753.72 and the Nasdaq gaining 1.1% to 23,043.38. Gold surged past $4,000 an ounce for the first time, peaking at $4,078. The Federal Reserve signaled more interest rate cuts after its first reduction in September. Tech stocks soared, led by AMD’s 24% jump on an AI chip deal with OpenAI.
9 October 2025
·····
Inside Deutsche Börse & Frankfurt Stock Exchange: Europe’s Financial Powerhouse Unveiled (2025 Update)

Inside Deutsche Börse & Frankfurt Stock Exchange: Europe’s Financial Powerhouse Unveiled (2025 Update)

Deutsche Börse AG operates the Frankfurt Stock Exchange, handling about 90% of German equity trading and hosting key indices like the DAX. Its stock trades near €230, valuing the group at €45–46 billion, with 2024 revenues at €5.83 billion. Recent moves include Ottobock’s IPO and partnerships with Circle and Chainlink. Analysts rate the stock Hold, with targets between €240 and €320.
9 October 2025
·
Gerresheimer Stock in Freefall After Another Profit Warning – Is the Worst Over?

Gerresheimer Stock in Freefall After Another Profit Warning – Is the Worst Over?

Gerresheimer cut its 2025 outlook after weak Q3 results, now expecting organic revenue to fall 2–4% and EBITDA margin to drop to 18.5–19%. Shares plunged 12% on Oct 9, hitting €33 and marking a year-to-date loss of over 50%. The company cited weak demand in cosmetics and oral liquid packaging. A BaFin probe into 2024 accounts and repeated guidance cuts have added pressure.
9 October 2025
··
MedTech Giant’s IPO Shakes Up Market: Ottobock’s Blockbuster Debut Revives IPO Hopes

MedTech Giant’s IPO Shakes Up Market: Ottobock’s Blockbuster Debut Revives IPO Hopes

Ottobock shares opened at €72 on Oct. 9, 2025, jumping 9% above the €66 IPO price and briefly reached €73 amid strong demand. The IPO raised €808 million, valuing the prosthetics maker at €4.2 billion, marking Germany’s largest listing in over a year. The Näder family retains over 80% ownership, with about 19% of shares in free float. Ottobock reported €1.43 billion revenue last year and employs around 9,300 people.
9 October 2025
BMW’s Profit Warning Shocks Markets – Tariffs and China Slowdown Spark Stock Slide

BMW’s Profit Warning Shocks Markets – Tariffs and China Slowdown Spark Stock Slide

BMW cut its 2025 profit forecast, citing weaker China sales and delayed U.S.-EU tariff relief. The company now expects a slight decline in pre-tax earnings and halved its auto division cash flow outlook to over €2.5 billion. Shares dropped as much as 9%, erasing up to €7 billion in market value. Mercedes-Benz stock also fell after similar China and tariff pressures.
9 October 2025
··
Nvidia’s $4 Trillion AI Stock Surge: Record Highs, Mega Deals & Bold Forecasts

Nvidia’s $4 Trillion AI Stock Surge: Record Highs, Mega Deals & Bold Forecasts

Nvidia’s stock surged to a record $190 in early October 2025, briefly pushing its market cap past $4 trillion and overtaking Apple. Quarterly revenue jumped 56% to $46.7 billion, driven by AI chip demand. Nvidia announced a $100 billion partnership with OpenAI and a $5 billion stake in Intel. AMD’s new deal to supply OpenAI with AI chips sent its shares up 30%, but Nvidia retains over 90% of the AI accelerator market.
9 October 2025
··
UiPath’s Automation Stock Soars on AI Buzz – Latest PATH Analysis & Outlook

UiPath’s Automation Stock Soars on AI Buzz – Latest PATH Analysis & Outlook

UiPath shares surged 5% to $15.58 on Oct. 8, nearing 2025 highs after a weeklong 20% rally and heavy trading volume. The move followed new AI partnerships with OpenAI, Google, NVIDIA, and Snowflake, and Q2 results that beat expectations with revenue up 14.6% to $362 million and a swing to a GAAP profit. Technical indicators show strong momentum but suggest overbought conditions. Wall Street consensus remains Hold.
9 October 2025
·
Euronext Paris Shocks Markets with Historic Roots, Surging Stocks & Bold 2025 Moves

Euronext Paris Shocks Markets with Historic Roots, Surging Stocks & Bold 2025 Moves

Euronext Paris, Europe’s second-largest stock exchange, lists nearly 800 companies valued over $4.5 trillion and operates the CAC 40 index. The CAC 40 closed near 8,045 on October 8, 2025, up about 10% year-to-date but below its March peak. Euronext N.V. joined the CAC 40 in September amid strong IPO activity and political turmoil following the French Prime Minister’s resignation. Average daily turnover is €4.1 billion.
9 October 2025
·····
Euronext Amsterdam Soars to New Heights: Europe’s Oldest Exchange Making History

Euronext Amsterdam Soars to New Heights: Europe’s Oldest Exchange Making History

Euronext Amsterdam, founded as the Amsterdam Stock Exchange in 1602, is the world’s oldest modern securities market. Now part of the Euronext group spanning seven countries, it lists over 140 companies including ASML, Shell, and ING. The exchange operates fully electronically from 9:00 a.m. to 5:30 p.m. CET, with oversight by Dutch regulators. Its AEX index had a free-float market cap of about €850 billion in early 2021.
9 October 2025
·····
London Stock Exchange at Record Highs – Inside the Historic Market’s Brexit Battle and 2025 Revival

London Stock Exchange at Record Highs – Inside the Historic Market’s Brexit Battle and 2025 Revival

The FTSE 100 closed at a record 9,548.87 on October 8, 2025, lifted by bank and gold miner stocks. London saw only 18 IPOs in 2024 and just three in the first nine months of 2025, the slowest pace since 2010. Over 150 companies have delisted or moved abroad since early 2024. The LSE lists firms from over 60 countries and runs one of the world’s longest trading days.
9 October 2025
·
1 … 1,328 1,329 1,330 1,331 1,332 … 1,371

Stock Market Today

  • Ocugen (OCGN) Shows Strong Momentum Amid Gene Therapy Pipeline Developments
    April 5, 2026, 1:25 AM EDT. Ocugen's (OCGN) stock displayed notable volatility recently with a 30-day return of 11.18% and a 1-year gain of 170.39%, signaling growing momentum. Trading at $1.79, its share price remains well below analysts' average target of $11.57, reflecting optimism about its late-stage gene therapy candidates like OCU400 and OCU410. These therapies target large, unmet medical needs and could drive substantial future revenue. However, reliance on unapproved treatments and ongoing cash burn presents risks, with trial setbacks or funding shortfalls potentially impacting valuations. Investors are encouraged to consider both growth potential and key warning signs before positioning in OCGN shares.
Go toTop